TrialInvestigational new drugs2015

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

B J Eigl et al.PubMed ↗Publisher ↗

No numbers read from the abstract.